Effect of an α-glucosidase inhibitor (voglibose), in combination with sulphonylureas, on glycaemic control in type 2 diabetes patients

Journal of International Medical Research

Volumn 26, Issue 5, 1998, Pages 219-232

  Saito, N ^a   Sakai, H ^b   Suzuki, S ^c   Sekihara, H ^d   Yajima, Y ^e  

^a ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c SHOWA UNIVERSITY FUJIGAOKA HOSPITAL   (Japan)

^d YOKOHAMA CITY UNIVERSITY   (Japan)

^e KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Fasting plasma glucose; Glycated haemoglobin; Sulphonylureas; Two hour post prandial plasma glucose; Type 2 diabetes; Voglibose; glucosidase innhibitors

Indexed keywords

ALPHA GLUCOSIDASE; GLIBENCLAMIDE; GLICLAZIDE; GLYCOSYLATED HEMOGLOBIN; SULFONYLUREA; VOGLIBOSE;

ADULT; AGED; ARTICLE; BODY WEIGHT; CLINICAL TRIAL; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL DRUG ADMINISTRATION; RASH; VASCULAR DISEASE;

EID: 0032446801     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/030006059802600501     Document Type: Article

References (36)

1. Zatz R, Brenner BM: Pathogenesis of diabetic microangiopathy: the hemodynamic view. Am J Med 1986; 80: 443-453.
2. Brach BB, Blackard W, Rothschild H: A review of deaths due to suspended lactic acidosis at a large metropolitan hospital. South Med J 1975; 68: 202-205.
3. The Physician's Guide to Type II Diabetes (NIDDM): Management of Type II Diabetes Mellitus (Rifkin H, ed). New York: American Diabetes Association, 1984; 20-52.
4. Toto Y: Glucosidase inhibitor. Diabetes Frontier 1992; 3: 557-564.
5. Rossetti I, Giaccari A, DeFronzo RA: Glucose toxicity. Diabetes Care 1990; 13: 610-630.
6. Unger RH, Grundy S: Hyperglycemia as an inducer as well a consequence of impaired islet cell function and insulin resistance: implications for the management of diabetes. Diabetologia 1985; 28: 19-121.
7. Grodsky GM: Pancreatic action of the sulfonylureas. FASEB J 1977; 36: 2714-2719.
8. Riddle MC, Hart JS, Bouma D, et al: Efficacy of bedtime NPH insulin with daytime sulfonylurea for subpopulation of type II diabetics. Diabetes Care 1989; 12: 623-629.
9. Clarke BF, Duncan LJP: Comparison of chlorpropamide and metformin treatment on weight and blood glucose response of uncontrolled obese diabetics. Lancet 1968; 1: 123-126.
10. Schmidt DD, Plus W: Amylase inhibitor. Dtsch Offenlegunsschrift 2003934. 1971;1.
11. Gray GM: Carbohydrate digestion and absorption: role of the small intestine. N Engl J Med 1975; 292: 1225-1230.
12. Kameda Y, Asano N, Yoshikawa M, et al: Valiolamine, a new α-glucosidase inhibiting aminocyclitol produced by Streptomyces hygroscipius. J Antibiot (Tokyo) 1984; 37: 1301-1307.
13. Horii S, Fukase H, Matsuo T, et al: Synthesis and α-D-glucosidase inhibitory activity of N-substituted valiomine derivatives as potential oral antidiabetic agents. J Med Chem 1986; 29: 1038-1046
14. Matsuo T, Okada H, Ideda H: Effect of an intestinal disaccharidase inhibitor (AO)-128), on obesity and diabetes. Am J Clin Nutr 1992; 55(suppl 1): 314-317.
15. Okada H, Miki N, Ikeda H, et al: Effect of disaccharidase inhibitor, AO-128, on postprandial hyperglycemia on rats. J Jpn Soc Nutr Food Sci 1992; 45: 27-31.
16. Goto Y, Baba S, Nakagawa S, et al: Utility of an α-glucosidase inhibitor, AO-128, in NIDDM-Phase III double-blind test. Jpn Advance in Medicine (Igaku no Ayumi) 1992; 160: 943-971.
17. Kiura K, Umeda F, Nawada A: Clinical utility of AO-128 long-term medication for non-insulin dependent diabetes mellitus (72 cases); Report 2. Jpn Clin Exp Med 1992; 69: 919-932.
18. Koizumi J, Mabuchi H, Takedoshi T, et al: Effects of oral hypoglycemic agents in combination controlled non-insulin dependent diabetes mellitus on AO-128. New Remed Clin 1992; 29: 241-252.
19. Umeda F, Mimura K, Nawada A: Effects of sulfonylureas long-term medication in combination controlled non-insulin dependent diabetes mellitus (NIDDM) on AD-128 (α-glucosidase inhibitor). Jpn J Clin Exp Med 1992; 69: 1309-1322.
20. Kawamori R, Morishima T, Shiba Y, et al: The effectiveness of a new disaccharidase inhibitor AO-128 in glycemic control of insulin-treated diabetic patients. J Jpn Diab Soc 1992; 35: 633-640.
21. Mimura K, Umeda F, Hisatomi A, et al: Clinical utility of AO-128 long-term medication for non-insulin dependent diabetes mellitus (72 cases); Report 2. Jpn Clin Exp Med 1992; 69: 235-244.
22. Matsuoka A, Takeuchi K, Makimura H, et al: Efficacy and safety of AO-128 long-term treated in non-insulin dependent diabetes mellitus. Med Consult New Remed 1992; 29: 255-265.
23. Kamiya F, Hayashi Y, Takeuchi T: Clinical utility of AO-128 long-term treatment in non-insulin dependent diabetes mellitus. J Adult Dis 1992; 22: 573-591.
24. Kohno S, Imamura K, Koji S, et al: Effects of α-glucosidase inhibitor on insulin sensitivity and decreased level of postprandial plasma glucose in NIDDM patients: evaluation by glucose clamp method (Part 1). Jpn J Clin Exp Med 1997; 74: 952-954.
25. Nao K, Ymazaki Y, Katsura K, et al: Glycemic threshold for prevention of diabetic retinopathy: a retrospective study of diabetic outpatients. J Jpn Diab Soc 1989; 32: 307-312.
26. Kawahara R, Nakagami T: Clinical study of treatments on diabetes mellitus: clinical factors for prevention of diabetic retinopathy. The Ministry of Health and Welfare, 1993; 267-269.
27. Umeno Y, Limori K, Endo M, et al: Combination effects of voglibose and sulfonylureas in non-insulin dependent diabetes mellitus (NIDDM) patients. Jpn Clin Exp Med 1997; 74: 739-744.
28. Iijima T, Makino T, Takahashi H, et al: Usefulness of combination therapy with sulfonylurea and α-glucosidase inhibitor (voglibose) in non-insulin dependent diabetes mellitus: effect of reducing the dose of sulfonylurea. Jpn Pharmacol Ther 1997; 25: 841-849.
29. Kanda T, Imano H, Matsushima H, et al: Usefulness of combination therapy with preprandial rapid-acting insulin injection and α-glucosidase inhibitor in non-obese NIDDM patients with secondary failure on oral hypoglycemic agents. J Jpn Diab Soc 1996; 39: 183-190.
30. Odaka H, Miki N, Ikeda H, Effect of intestinal disaccharidase inhibitor, AO-128, on carbohydrate, protein, fat, and vitamin absorption in rats. Jpn Pharmacol Ther 1991; 19: 4439-4450.
31. y. J Nutr Sci Vitaminol (Tokyo) 1991: 19: 4105-4117.
32. Matsuo T, Odaka H, Ikeda H: Effect of an intestinal disaccharidase inhibitor (AO-128) on obesity and diabetes. Am J Clin Nutr 1992; 55(suppl 1.1): 314-317.
33. Shimura Y, Odaka H, Ikeda H, et al: Obesity suppression and anti-diabetic activity on AO-128. Proceedings of the 7th Congress of Japan Aged Society Supporting Organization 1986; 210-211.
34. Inui Y, Kawata S, Matsuzawa Y, et al: Inhibitory effect of a new α-glucosidase inhibitor on fatty liver in zucker fatty rats. J Hepatol 1990; 10: 62-68.
35. Inui Y, Kawata S, Kohata R, et al: The effects of an α-glucosidase inhibitor on fatty liver in obesity. Jpn J Gastroenterol 1987; 84: 1639-1644.
36. Report of the Expert Committee on the diagnosis and the classification of diabetes mellitus. Diabetes Care 1997; 20: 1183-1197